Sterling Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Sterling Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.02K	Buy	280 +42	+18%	+$366	﹤0.01%	3136
2026 Q2	$2.48K	Sell	238 -75	-24%	-$556	﹤0.01%	2936
2026 Q1	$1.92K	Sell	313 -331	-51%	-$2.36K	﹤0.01%	3003
2025 Q4	$4.64K	Buy	644 +5	+0.8%	+$40	﹤0.01%	2914
2025 Q3	$6.53K	Buy	639 +416	+187%	+$4.68K	﹤0.01%	2689
2025 Q2	$2.32K	Buy	223 +209	+1,493%	+$2.23K	﹤0.01%	2883
2025 Q1	$185	Hold	14	–	–	﹤0.01%	3092
2024 Q4	$251	Buy	14 +7	+100%	+$142	﹤0.01%	3102
2024 Q3	$113	Buy	+7	New	+$109	﹤0.01%	3183

Other funds holding RNAC

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

CM Management Gulf Breeze, Florida $149M AUM 35.54% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Sterling Capital Management's RNAC Position: Q3 2026 in Review

Sterling Capital Management increased its Cartesian Therapeutics (RNAC) stake by 18% in Q3 2026, buying an estimated $366 and bringing the position to 280 shares worth $2.02K. The position accounts for ﹤0.01% of the portfolio, ranked #3136.

Sterling Capital Management first reported a position in RNAC in Q3 2024 and has held it in 9 quarters since. The position peaked at $6.53K in Q3 2025. 65 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

Sterling Capital Management held 280 shares of Cartesian Therapeutics worth $2.02K as of Q3 2026.
Sterling Capital Management bought 42 Cartesian Therapeutics shares in Q3 2026, an estimated $366.
Cartesian Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #3136 holding.
Sterling Capital Management first reported a position in Cartesian Therapeutics in Q3 2024 and has held it in 9 quarters since.
Sterling Capital Management's Cartesian Therapeutics position peaked at $6.53K in Q3 2025.
65 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.